References
- Hodis HN, Mack WJ, Lobo RA, et al. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001;135:939–53
- Billon-Gales A, Fontaine C, Douin-Echinard V, et al. Endothelial estrogen receptor-alpha plays a crucial role in the atheroprotective action of 17beta-estradiol in low-density lipoprotein receptor-deficient mice. Circulation 2009;120:2567–76
- Torii R, Shiomi M, Ito T, et al. Cholesterol-fed ovariectomized monkeys are good animal models for human atherosclerosis of postmenopausal women. Primates 2003;44:247–52
- Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321–33
- Karas R, Clarkson TB. Considerations in interpreting the cardiovascular effects of hormone replacement observed in WHI: timing is everything. Menopausal Med 2003;8–12
- Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. Bmj 2012;345:e6409
- Back M, Hansson GK. Anti-inflammatory therapies for atherosclerosis. Nat Rev Cardiol 2015;12:199–211
- Simoncini T, Scorticati C, Mannella P, et al. Estrogen receptor alpha interacts with Galpha13 to drive actin remodeling and endothelial cell migration via the RhoA/Rho kinase/moesin pathway. Mol Endocrinol 2006;20:1756–71
- Zheng S, Chen X, Hong S, et al. 17β-Estradiol inhibits vascular smooth muscle cell migration via up-regulation of striatin protein. Gynecol Endocrinol 2015;31:618–24
- Cheng W, Zhao Y, Wang S, Jiang F. Tumor necrosis factor-related apoptosis-inducing ligand in vascular inflammation and atherosclerosis: a protector or culprit? Vascul Pharmacol 2014;63:135–44
- Azahri NS, Di Bartolo BA, Khachigian LM, Kavurma MM. Sp1, acetylated histone-3 and p300 regulate TRAIL transcription: mechanisms of PDGF-BB-mediated VSMC proliferation and migration. J Cell Biochem 2012;113:2597–606
- Zauli G, Tisato V, Melloni E, et al. Inverse correlation between circulating levels of TNF-related apoptosis-inducing ligand and 17β-estradiol. J Clin Endocrinol Metab 2014;99:E659–64
- Lacolley P, Regnault V, Nicoletti A, et al. The vascular smooth muscle cell in arterial pathology: a cell that can take on multiple roles. Cardiovasc Res 2012;95:194–204
- Stuckey DW, Shah K. TRAIL on trial: preclinical advances in cancer therapy. Trends Mol Med 2013;19:685–94
- Watt V, Chamberlain J, Steiner T, et al. TRAIL attenuates the development of atherosclerosis in apolipoprotein E deficient mice. Atherosclerosis 2011;215:348–54
- Chen PL, Easton A. Apoptotic phenotype alters the capacity of tumor necrosis factor-related apoptosis-inducing ligand to induce human vascular endothelial activation. J Vasc Res 2008;45:111–22
- Kavurma MM, Schoppet M, Bobryshev YV, et al. TRAIL stimulates proliferation of vascular smooth muscle cells via activation of NF-kappaB and induction of insulin-like growth factor-1 receptor. J Biol Chem 2008;283:7754–62
- Tecchio C, Huber V, Scapini P, et al. IFNalpha-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells. Blood 2004;103:3837–44
- Allen JE, El-Deiry WS. Regulation of the human TRAIL gene. Cancer Biol Ther 2012;13:1143–51
- Baetu TM, Kwon H, Sharma S, et al. Disruption of NF-kappaB signaling reveals a novel role for NF-kappaB in the regulation of TNF-related apoptosis-inducing ligand expression. J Immunol 2001;167:3164–73
- Cippitelli M, Fionda C, Di Bona D, et al. The cyclopentenone-type prostaglandin 15-deoxy-delta 12,14-prostaglandin J2 inhibits CD95 ligand gene expression in T lymphocytes: interference with promoter activation via peroxisome proliferator-activated receptor-gamma-independent mechanisms. J Immunol 2003;170:4578–92
- Simoncini T, Mannella P, Fornari L, et al. Differential signal transduction of progesterone and medroxyprogesterone acetate in human endothelial cells. Endocrinology 2004;145:5745–56